Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can ultrasound predict cancer drug response earlier?

NCT ID NCT02666690

Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial is testing whether contrast-enhanced ultrasound (CEUS) can reliably measure tumor blood flow in people with metastatic cancers like GIST, breast, kidney, colon, rectal, or melanoma. Participants will have two ultrasound scans before starting anti-angiogenic treatment, and again at day 15 and day 30. The goal is to see if the measurements are consistent enough to use CEUS as an early indicator of whether these drugs are working.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Contrast-enhanced ultrasound (CEUS)
What this could lead to
If the measurements are consistent, CEUS could become a reliable early test for whether anti-angiogenic drugs are working, helping doctors adjust treatment sooner.
What could go wrong
This is a small, early-stage variability study, not a treatment test. The results may not translate into routine clinical use, and the technique's reliability could vary across different tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

59 people

The number who actually took part.

Start date

Jul 2011

Finished

Oct 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient being treated at IGR for metastatic cancer by anti-angiogenic (s) drug (s) in the following indications: * Gastrointestinal sarcoma (GIST) * Breast Cancers * Kidney Cancers * Colorectal Cancers * Melanoma These anti-angiogenic drugs are used alone or in combination: Bevacizumab (Avastin), imatinib (Gleevec), Sorafenib (Nexavar), sunitinib (Sutent), Everolimus (Afinitor) Temsirolimus (Torisel), ... (non exhaustive list). 2. With at least one clearly identified metastatic tumor lesion (and accessible to ultrasound for acquisition 3 minutes without losing the target), measuring more than 2 cm, less than 50% of the volume is necrotic. Metastatic lesions are: * Liver (30 patients) * Or outside the liver (30 patients) 3. Physiological Age: 18-80 years 4. performance status \<2 5. Patient information and signature of informed consent Exclusion Criteria: 1. Background known hypersensitivity to sulfur hexafluoride or one of the components, 2. recent history of acute coronary syndrome or unstable ischemic heart disease, 3. Acute heart failure, heart failure stage III or IV, or severe rhythm disorders, 4. uncontrolled hypertension or severe pulmonary hypertension, 5. Right-Left Shunt, 6. Respiratory Distress Syndrome, 7. Patient without vascularized tumor (without contrast enhancement) 8. patient whose antiangiogenic has already started, 9. Pregnant woman likely to be or breastfeeding, 10. Persons deprived of liberty or under guardianship, 11. Unable to submit to medical monitoring of the trial for geographical, social or psychological reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast metastatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer colorectal cancer gastrointestinal stromal tumor metastatic malignant neoplasm metastatic malignant neoplasm in the colon metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast metastatic cancer Colon metastatic cancer Gist metastatic cancer Kidney metastatic cancer Rectal metastatic cancer

Contacts and locations

Locations

  • Gustave Roussy Cancer Campus Grand Paris

    Villejuif, Val de Marne, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.